Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 4
2014 4
2015 11
2016 7
2017 15
2018 6
2019 12
2020 11
2021 18
2022 23
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Arid1a regulates insulin sensitivity and lipid metabolism.
Qu YL, Deng CH, Luo Q, Shang XY, Wu JX, Shi Y, Wang L, Han ZG. Qu YL, et al. EBioMedicine. 2019 Apr;42:481-493. doi: 10.1016/j.ebiom.2019.03.021. Epub 2019 Mar 14. EBioMedicine. 2019. PMID: 30879920 Free PMC article.
In vitro, Arid1a deletion in isolated hepatocytes directly leads to free fatty acid-induced lipid accumulation and insulin resistance. ...INTERPRETATION: These findings reveal that targeting Arid1a might be a promising therapeutic strategy for liver steatosis …
In vitro, Arid1a deletion in isolated hepatocytes directly leads to free fatty acid-induced lipid accumulation and insulin resistance …
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Zucman-Rossi J, et al. Gastroenterology. 2015 Oct;149(5):1226-1239.e4. doi: 10.1053/j.gastro.2015.05.061. Epub 2015 Jun 20. Gastroenterology. 2015. PMID: 26099527 Review.
TP53 and CTNNB1 are the next most prevalent mutations, affecting 25%-30% of HCC patients, that, in addition to low-frequency mutated genes (eg, AXIN1, ARID2, ARID1A, TSC1/TSC2, RPS6KA3, KEAP1, MLL2), help define some of the core deregulated pathways in HCC. ...
TP53 and CTNNB1 are the next most prevalent mutations, affecting 25%-30% of HCC patients, that, in addition to low-frequency mutated genes ( …
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Montal R, et al. J Hepatol. 2020 Aug;73(2):315-327. doi: 10.1016/j.jhep.2020.03.008. Epub 2020 Mar 12. J Hepatol. 2020. PMID: 32173382 Free PMC article.
Molecular findings were validated in an external set of 181 biliary tract tumors from the ICGC. RESULTS: KRAS (36.7%), TP53 (34.7%), ARID1A (14%) and SMAD4 (10.7%) were the most prevalent mutations, with 25% of tumors having a putative actionable genomic alteration accordi …
Molecular findings were validated in an external set of 181 biliary tract tumors from the ICGC. RESULTS: KRAS (36.7%), TP53 (34.7%), ARID …
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW; TIGER-LC Consortium. Chaisaingmongkol J, et al. Cancer Cell. 2017 Jul 10;32(1):57-70.e3. doi: 10.1016/j.ccell.2017.05.009. Epub 2017 Jun 22. Cancer Cell. 2017. PMID: 28648284 Free PMC article.
Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We identified common molecular subtypes linked to similar prognosis among 199 Thai ICC and HCC patients th …
Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiologi …
"Cancer in ARID1A-Coffin-Siris syndrome: Review and report of a child with hepatoblastoma".
Cárcamo B, Masotto B, Baquero-Vaquer A, Ceballos-Saenz D, Zapata-Aldana E. Cárcamo B, et al. Eur J Med Genet. 2022 Nov;65(11):104600. doi: 10.1016/j.ejmg.2022.104600. Epub 2022 Aug 29. Eur J Med Genet. 2022. PMID: 36049608 Review.
Two of these malignancies including one acute lymphoid leukemia and one hepatoblastoma were reported in ARID1A-associated CSS (ARID1A-CSS). Alterations in ARID1A are among the most common molecular aberrations in human cancer. ...The role of ARID1A in …
Two of these malignancies including one acute lymphoid leukemia and one hepatoblastoma were reported in ARID1A-associated CSS (ARI …
Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.
Xing T, Li L, Chen Y, Ju G, Li G, Zhu X, Ren Y, Zhao J, Cheng Z, Li Y, Xu D, Liang J. Xing T, et al. Cell Rep Med. 2023 Nov 21;4(11):101264. doi: 10.1016/j.xcrm.2023.101264. Epub 2023 Nov 7. Cell Rep Med. 2023. PMID: 37939712 Free PMC article.
ARID1A is among the most commonly mutated tumor suppressor genes in hepatocellular carcinoma (HCC). In this study, we conduct a CRISPR-Cas9 synthetic lethality screen using ARID1A-deficient HCC cells to identify approaches to treat HCC patients harboring ARID1A …
ARID1A is among the most commonly mutated tumor suppressor genes in hepatocellular carcinoma (HCC). In this study, we conduct a CRISP …
Unraveling the Epigenetic Basis of Liver Development, Regeneration and Disease.
Macchi F, Sadler KC. Macchi F, et al. Trends Genet. 2020 Aug;36(8):587-597. doi: 10.1016/j.tig.2020.05.002. Epub 2020 May 30. Trends Genet. 2020. PMID: 32487496 Review.
A wealth of studies over several decades has revealed an epigenetic prepattern that determines the competence of cellular differentiation in the developing liver. More recently, studies focused on the impact of epigenetic factors during liver regeneration suggest th …
A wealth of studies over several decades has revealed an epigenetic prepattern that determines the competence of cellular differentiation in …
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer.
Sun X, Wang SC, Wei Y, Luo X, Jia Y, Li L, Gopal P, Zhu M, Nassour I, Chuang JC, Maples T, Celen C, Nguyen LH, Wu L, Fu S, Li W, Hui L, Tian F, Ji Y, Zhang S, Sorouri M, Hwang TH, Letzig L, James L, Wang Z, Yopp AC, Singal AG, Zhu H. Sun X, et al. Cancer Cell. 2017 Nov 13;32(5):574-589.e6. doi: 10.1016/j.ccell.2017.10.007. Cancer Cell. 2017. PMID: 29136504 Free PMC article.
In some hepatocellular carcinoma patients, ARID1A was highly expressed in primary tumors but not in metastatic lesions, suggesting that ARID1A can be lost after initiation. Mice with liver-specific homozygous or heterozygous Arid1a loss were resistant …
In some hepatocellular carcinoma patients, ARID1A was highly expressed in primary tumors but not in metastatic lesions, suggesting th …
Inhibition of Arid1a increases stem/progenitor cell-like properties of liver cancer.
Wang L, Deng CH, Luo Q, Su XB, Shang XY, Song SJ, Cheng S, Qu YL, Zou X, Shi Y, Wang Q, Du SC, Han ZG. Wang L, et al. Cancer Lett. 2022 Oct 10;546:215869. doi: 10.1016/j.canlet.2022.215869. Epub 2022 Aug 11. Cancer Lett. 2022. PMID: 35964817
However, the function of ARID1A in the pathogenesis of liver cancer remains controversial. ...Mechanistic studies revealed that Arid1a loss remodeled the chromatin accessibility of some genes related to liver functions. ...
However, the function of ARID1A in the pathogenesis of liver cancer remains controversial. ...Mechanistic studies revealed tha …
ARID1A Is a Prognostic Biomarker and Associated with Immune Infiltrates in Hepatocellular Carcinoma.
Feng Y, Tang X, Li C, Su Y, Wang X, Li N, Zhang A, Jiang F, Wu C. Feng Y, et al. Can J Gastroenterol Hepatol. 2022 Jan 4;2022:3163955. doi: 10.1155/2022/3163955. eCollection 2022. Can J Gastroenterol Hepatol. 2022. PMID: 35028302 Free PMC article.
ARID1A was shown to be a risk indicator of overall survival on its own. ARID1A expression is inversely proportional to immune cell infiltration. ...
ARID1A was shown to be a risk indicator of overall survival on its own. ARID1A expression is inversely proportional to immune …
115 results